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Abstract: The chiral structure of antibiotic vancomycin (Van) was exploited as an innovative
coordination sphere for the preparation of an IrCp* based hybrid catalysts. We found that Van is
able to coordinate iridium (Ir(III)) and the complexation was demonstrated by several analytical
techniques such as MALDI-TOF, UV, Circular dichroism (CD), Raman IR, and NMR. The hybrid
system so obtained was employed in the Asymmetric Transfer Hydrogenation (ATH) of cyclic imines
allowing to obtain a valuable 61% e.e. (R) in the asymmetric reduction of quinaldine 2. The catalytic
system exhibited a saturation kinetics with a calculated efficiency of Kcat/KM = 0.688 h−1mM−1.
Keywords: glycopeptides; hybrid catalyst; asymmetric hydrogen transfer
Vancomycin (Van) is a front-line glycopeptide antibiotic produced by Streptomyces orientalis and active
against Gram positive infections. Its activity is due to a selective binding to the D-Ala-D-Ala terminus of
peptidoglycan precursor hampering the formation of the bacterial cell wall [1,2]. Recently, it was found
that several biological effects of Van are also related to its ability to bind both Cu(II) and Zn(II) metal ions
under physiological/neutral conditions [3–5]. Van is a macrocycle characterized by axially chiral biaryl
structural motifs [6–9] connected to a glycopeptide chain endowed with different groups promoting
dipole-dipole interactions and pi-pi interactions. Its copper binding site involves N-terminal imino
nitrogen, two consecutive nitrogen atoms in the peptide chain, and one oxygen atom from asparagine
amide group. This ability to form a stable complex with transition metals, the atropoisomerism induced
by the restricted rotation around the aryl-aryl bonds, and the macrocyclic chiral basket-like structure
all make Van an interesting, although yet unexplored, ligand for asymmetric catalysis.
In the last decades, the development of hybrid catalysts that combine the advantages of chemical
catalysts and biocatalysis, has launched an original approach allowing high selectivity and specificity
to be merged with a wide scope of reactivity and substrates. The widespread presence of metal ions
in biological systems and the possibility of using well-known natural structures as ligands in metal
complexes have inspired different research groups to exploit biodiversity and to investigate new
artificial systems, such as the combination of the reactive metals with different biological scaffolds (e.g.,
proteins, DNA, and peptides) [10–17].
In this work, we verified the ability of Van to coordinate Ir(III) in a different manner compared to
Cu(II) and Zn(II). The catalytic performance of such a complex in which Van represented the source
of chirality in transition metal complex, was evaluated in the asymmetric reduction of cyclic imines.
This reaction is a key tool to produce complex alkaloids and un-natural β-amino acids as well as
important pharmaceutical intermediates [18–21]. In this regard, Asymmetric Transfer Hydrogenation
(ATH) provides a valuable process and Ir(III) catalyzed ATH has been recently widely investigated
due to the possibility to use environmentally friendly reaction conditions as the aqueous media for
both the reduction of imines and ketones [22–28]. Generally, ruthenium and rhodium were used as
co-factor for transfer hydrogenation reactions for involving ketones, even if in the last decades many
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researchers shed light on the potential use of iridium based catalysts, thus expanding the scope of
reaction to imines. These catalytic systems afforded better results both in terms of enantioselectivity
and conversion rate under aqueous conditions, desirable and green chemistry compatible ones [29–32].
Furthermore, in our group, we recently developed different catalytic artificial imine reductases in
which the active moiety was represented by a η5-piano stool Ir(III) complex [33,34].
Van ability to coordinate an Ir(III) center was assessed in solution using dimeric [IrCp*Cl2]2 in
a 0.5:1 ratio with Van. The formation of the complex was confirmed by several analytical techniques
such as MALDI-TOF, UV, Circular dichroism (CD), Raman IR, and NMR. First, MALDI-TOF experiments
showed the presence of the molecular peak corresponding to a monomer complex, while no peaks
corresponding to alternative complexes were observed (see SI, Figure S1). The coordination of Van
to the iridium metal center was then confirmed by the bathochromic shift of the metal-to-ligand
charge transfer transition (MLCT) band [35] in the UV spectra (Eλ436nm = 6 × 103 M−1cm−1) [36,37].
Interestingly, the addition of [IrCp*Cl2]2 to a Van solution caused a shift of the maximum absorbance
from 417 nm for [IrCp*Cl2]2 alone to 429 nm for the [Ir(Cp*)(Van)Cl] complex [38,39] (see SI, Figure S2).
Circular dichroism (CD) experiments on free vancomycin and on the Ir/Van 1:1 complex further
confirmed that the complexation between the chiral macromolecule and the metal was effective.
In Figure 1, the CD spectra in acetate buffer (pH 5, on the left) and in phosphate buffer (pH 8,
on the right) are reported. By comparing free Van spectra (black lines) and the Van/Ir 1:1 complex
spectra (red lines), the appearance of negative Cotton effects at around 360 nm together with slightly
positive shoulders at around 415 nm was observed both at acidic and basic pH. The binding with
the metal is particularly evident by comparing the spectra of the free Van (black lines) with the ones
obtained by subtracting Van contribution from the 1:1 mixture spectra. The resulting curves (blue lines)
showed the induction of chirality at the metal center, as the observed Cotton effects could be ascribable
only to iridium energetic transitions. Furthermore, looking at the 1:1 complex spectra, a different
behavior of Van at 285 nm band is observed depending on pH. In acetate buffer, an increase in the
intensity was observed while the intensity of the same band decreases in phosphate buffer. From these
findings we can assume that Van aromatic rings are involved in the coordination, but assume a different
conformation depending on the environment.
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Figure 1. Circular dichroism (CD) spectra of free Vancomycin (Van) (black line) and Van/Ir 1:1 complex
(red line) recorded in acetate buffer (pH 5, on the left) and in phosphate buffer (pH 8, on the right) are
reported. The blue line is the obtained spectrum by subtracting Van contribution from the 1:1 complex.
The concentration of Ir(III) is 2.5 mM.
NMR experiments were then performed to shed more light on the complexation mode. From both
1H and 13C NMR spectra, it was established that the iridium coordination affected both the sugar
and the aromatic parts of Van (Figure 2 and SI), suggesting a conformational rearrangement of the
molecule upon binding. The effect on the aromatic rings and on the CH3 groups was further confirmed
by RAMAN spectroscopy [40,41] (see SI, Figure S5).
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The coordination mode between the chemical groups involved with Van and the metal ion, however,
remains uncertain in the absence of crystals suitable for X-ray structural assignment. This unclear
coordination mode could depend on the different Lewis bases present in the Van: the two adjacent
but not consecutive nitrogens of the amide and -NHCH3 group, the carboxylate on the C-terminus,
the 2,2-biphenolic units, and the oxygen atom of the Asn sidechain. All these ones could be a possible
coordination site between the Van and the iridium metal center, in function of the pH and of the
ionic strength.
The [Ir(Cp*)(Van)Cl] complex was prepared in situ after 1 h pre-complexation time and its catalytic
activity was evaluated in the asymmetric transfer hydrogenation reactions of three cyclic imines
A, B and C, having different electronic and steric properties, and chosen for being precursors of
pharmaceutically valuable intermediates [42] (Scheme 1).
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Table 1. In situ ATH of different cyclic imines with the [Ir(Cp*)(Van)Cl] complex.
Entry Buffer
Sub 1
Conv. %
(e.e.%)
Sub 2
Conv. %
(e.e.%)
Sub3
Conv. %
(e.e.%)
1 Phosphate0.1 M pH 8 56 (20, R) (a) 30 (36, R) 92 (42, R)
2 MOPS1.2 M pH 7.8 34 (rac) 40 (46, R) 64 (rac)
3 MES1.2 M pH 7 82 (4, S) 30 (9, R) 60 (4, R)
4 MES1.2 M pH 6 40 (4, S) 67 (12, R) 25 (rac)
5 Acetate0.1 M pH 5 34 (3, S) 20 (21, R) 30 (rac)
6 MES1.2 M pH 5 75 (5, S) 35 (61, R) 20 (30, S)
Reaction conditions: substrate concentration 16 mM, 4 mol% Van, 1 mol% [IrCp*Cl2]2, buffer, HCOONa 3 M, 18 h
and at 25 ◦C. (a) substrate 16 mM, 8 mol% Van, 1 mol% [IrCp*Cl2]2, buffer, HCOONa 3 M, 18 h and at 25 ◦C.
The best result in terms of enantioselectivity in the ATH of quinaldine 2 was achieved by
performing the reaction in a MES 1.2 M buffer at pH 5 with a significant 61% e.e. despite a modest 35%
conversion rate (Table 1, Entry 6, Sub 2). Interestingly, an inversion of configuration was observed in
the ATH of 3-methylbenzo[d]isothiazole 1,1-dioxide 3 going from basic pH (42% e.e. for (R) enantiomer
in phosphate buffer 0.1 M pH 8, Table 1, Entry 1, Sub 3) to acid one (30% e.e. for (S) enantiomer in
MES buffer 1.2 M pH 5, Table 1, Entry 6, Sub 3) along with a significant difference in the reaction rates
(from 92% conversion to 20%).
This behavior could be explained in terms of both different electronic and steric properties of the
imine substrates depending on the buffer solution, the pH and the ionic strength [47–49], in interaction
with the different stabilized conformation of the [Ir(Cp*)(Van)Cl] complex [32,50].
Moreover, with the aim to evaluate the catalytic efficiency of the system here proposed,
we determined the kinetic parameters and consequently its efficiency defined by Kcat/KM ratio [51–53]
(see SI, Figure S6).
The affinity of Substrate 1, 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline was taken into
consideration for comparison with other systems based on supramolecular interaction, reported in
literature i.e., the systems based on the streptavidin/biotin technology. The kinetic parameters revealed
that this catalyst could be considered an hybrid system with the substrate possessing a high affinity
for the [Ir(Cp*)(Van)Cl] complex (KM = 1.4 mM), while the catalytic activity and the overall efficiency
(Kcat = 0.978 h−1, Kcat/KM = 0.688 h−1mM−1) is comparable to other artificial systems [54,55].
In conclusion, a hybrid catalyst generated from the interaction of the steric hindered and
rigid vancomycin with Ir(III) metal complex was studied and characterized. The conformational
rearrangement of vancomycin, caused by the complexation with IrCp*, was evinced by different
analytical characterization techniques. The capability of this new hybrid catalyst to reduce different
cyclic imines was evaluated in aqueous media under mild reaction conditions affording the reaction
product with moderate to appreciable enantioselectivity. Particularly interesting were the results
obtained in the asymmetric reduction of quinaldine 2 and of 3-methylbenzo[d]isothiazole 1,1-dioxide 3.
While for 2 an appreciable 61% e.e. was achieved in MES Buffer 1.2 M pH 5, for Substrate 3 a fascinating
inversion of configuration occurred along with a good 42% e.e. by changing the buffer and its pH.
This behavior might suggest the possibility for Van to create a different chiral coordination sphere
around the catalytic center depending on the pH, ionic strength, and on the buffer, influencing the
catalytic performance of the catalyst in function of the employed substrate. Indeed, the reproducibility
of the in situ complexation mode was confirmed by the results obtained in independent experiments
thus giving us a reasonable prospect for the possibility to improve the versatility of this system and the
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possibility to apply it to different types of enantioselective reactions, eventually changing the metal
center to rhodium or ruthenium.
1. Experimental Section
In general, vancomycin was commercially available. [IrCp*Cl2]2 was synthetized as reported in
the literature [56]. Catalytic reactions were monitored by HPLC analysis with a Merck–Hitachi L-7100
(Merck, Rome, Italy) equipped with a Detector UV6000LP (Thermo Fisher, Monza, Italy) and a chiral
column (Chiralcel OD-H, Diacel, Tours, France). HR-MS analyses were performed by using a QTof
Synapt G2 Si spectrometer (Waters, Milan, Italy) with an electrospray ionization source. The spectra
were obtained by direct infusion of a sample solution in MeOH under ionization, ESI positive. 1H and
13C NMR spectra were recorded in D2O/[d6]DMSO (1% v/v) on Bruker Avance (Bruker, Milan, Italy)
600 MHz. Chemical shifts (δ) are expressed in parts per million (ppm). All the experiments were
recorded at 298 K using TMS as the internal standard.
1.1. General Procedure for Synthesis of [Ir(Cp*)(Van)Cl] Complex
Van (1.1 eq, 25 mmM) was dissolved in 1 mL of water or the appropriate buffer. The dimer
[IrCp*Cl2]2 (0.5 eq, 25 mM), opportunely dissolved in DMSO (10 µL), was added and the suspension
was stirred for 1 h at room temperature. Then the yellow solution was used without further purification.
1.2. General Procedure for Asymmetric Transfer Hydrogenation.
[IrCp*Cl2]2 (1% mol) and Van (4% mol) were dissolved in 1 mL of MES buffer (MES 1.2 M,
HCOONa 3 M, final pH 5) and stirred for 60 min at 25 ◦C. The substrate (final concentration 16 mM)
was added to the catalyst solution. The reaction was stirred for 18 h at 25 ◦C. At the end of the reaction
10 µL of NaOH 10 N was added and the aqueous media was extracted with CH2Cl2 for Substrate 1
and 2 and with ethyl acetate for Substrate 3. The organic layers were dried with anhydrous Na2SO4,
filtered, and the solvent was removed under vacuum to be analyzed by HPLC equipped with a chiral
column determining conversion and enantiomeric excess.
1.3. Circular Dichroism
The samples were prepared by diluting a stock solution of the [Ir(Cp*)(Van)Cl] complex (1 M
water with 1% DMSO) to a final concentration of 2.5 mM in the appropriate buffer and sonicated
for complete dissolution. Spectra were obtained from 280 to 450 nm with a 0.1 nm step and 1 s
collection time per step, taking three averages. The spectrum of the buffer solution was subtracted
to eliminate interference from cell, solvent, and optical equipment. The CD spectra were plotted as
ellipticity θ (degree × cm2 × dmol−1) versus wavelength λ (nm). Noise-reduction was obtained using
a Fourier-transform filter program from Jasco.
1.4. Kinetic Experiments
The stock solutions of the substrate were prepared in different concentrations (0.3–16 mM in DMF).
Aliquots of 10µl of the solution were mixture with 10µL of stock solution of the [Ir(Cp*)(Van)Cl] complex
(32 mM in DMF) in 1 mL buffer (MOPS 1.2 M, HCOONa 3 M, pH 5). After a suitable period of time
(1–5 h), samples were collected and processed according to the experimental protocol. Conversions were
determined by integration of the corresponding HPLC signals, using the calibration curve to correct for
the difference in extinction coefficient for Substrate 1. (Similar enantioselectivities were measured as in
the experiments conducted under standard conditions). The curves for the saturation kinetics were
determined in triplicate. Values obtained were plotted against the corresponding reaction times [57].
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